文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

西妥昔单抗联合FOLFOXIRI对比西妥昔单抗联合FOLFOX作为RAS/BRAF野生型初始不可切除结直肠癌肝转移患者的转化方案(TRICE试验):一项随机对照试验

Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial.
PubMed 文献 · PLoS Med · 2024-05-10

TRICE试验在7个医学中心纳入146例RAS/BRAF野生型初始不可切除结直肠癌肝转移患者,1:1随机接受西妥昔单抗联合FOLFOXIRI(三药组,n=72)或西妥昔单抗联合FOLFOX(双药组,n=74)转化治疗。主要终点客观缓解率在三药组84.7%与双药组79.7%之间无显著差异(OR 0.70,95%CI 0.30–1.67,P=0.42)。三药组中位肿瘤缓解深度更高(59.6% vs 55.0%,P=0.039),但R0/R1切除率与无进展生存期无显著改善,且3级及以上中性粒细胞减少和腹泻发生率更高。

要点

  • 三药组与双药组客观缓解率分别为84.7%和79.7%,无显著差异(OR 0.70,95%CI 0.30–1.67)。
  • 三药组中位肿瘤缓解深度59.6%高于双药组55.0%,但R0/R1切除率无显著差异(54.2% vs 52.7%)。
  • 三药组3级及以上中性粒细胞减少(44.1% vs 27.0%)和腹泻(5.9% vs 0%)发生率更高。

核心结论

  • 西妥昔单抗联合FOLFOXIRI较西妥昔单抗联合FOLFOX未显著改善客观缓解率,肿瘤缓解深度提高但未转化为R0切除率或无进展生存期改善,且三药组治疗相关毒性增加。

研究设计与样本

  • 开放标签随机对照试验,2018年4月至2022年12月在中国7个医学中心开展。
  • 纳入146例RAS/BRAF野生型初始不可切除结直肠癌肝转移患者,按肿瘤位置和可切除性分层区组随机1:1分组。
  • 西妥昔单抗联合FOLFOXIRI组72例,西妥昔单抗联合FOLFOX组74例。
  • 主要终点为客观缓解率,次要终点包括中位肿瘤缓解深度、早期肿瘤缩小、R0切除率、无进展生存期、总生存期(分析时未成熟)和安全性。

主要发现

  • 客观缓解率在三药组为84.7%,双药组为79.7%(OR 0.70,95%CI 0.30–1.67,卡方P=0.42),无显著差异。
  • 早期肿瘤缩小率在三药组为80.6%(58/72),双药组为77.0%(57/74)(OR 0.82,95%CI 0.37–1.83,卡方P=0.63),无显著差异。
  • 中位肿瘤缓解深度在三药组为59.6%(IQR 50.0–69.7),双药组为55.0%(IQR 42.8–63.8)(Mann-Whitney P=0.039)。
  • R0/R1切除率(联合或不联合射频消融/立体定向体部放疗)在三药组为54.2%(39/72),双药组为52.7%(39/74)。
  • 中位随访26.2个月(IQR 12.8–40.5),中位无进展生存期在三药组为11.8个月,双药组为13.4个月(HR 0.74,95%CI 0.50–1.11,Log-rank P=0.14)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究主要局限性包括关于切除可行性的主观手术决策存在固有偏倚。
  • 缺乏对客观缓解率和切除的集中评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It remains unclear whether intensification of the chemotherapy backbone in tandem with an anti-EGFR can confer superior clinical outcomes in a cohort of RAS/BRAF wild-type colorectal cancer (CRC) patients with initially unresectable colorectal liver metastases (CRLM). To that end, we sought to comparatively evaluate the efficacy and safety of cetuximab plus FOLFOXIRI (triplet arm) versus cetuximab plus FOLFOX (doublet arm) as a conversion regimen (i.e., unresectable to resectable) in CRC patients with unresectable CRLM. METHODS AND FINDINGS: This open-label, randomized clinical trial was conducted from April 2018 to December 2022 in 7 medical centers across China, enrolling 146 RAS/BRAF wild-type CRC patients with initially unresectable CRLM. A stratified blocked randomization method was utilized to assign patients (1:1) to either the cetuximab plus FOLFOXIRI (n = 72) or cetuximab plus FOLFOX (n = 74) treatment arms. Stratification factors were tumor location (left versus right) and resectability (technically unresectable versus ≥5 metastases). The primary outcome was the objective response rate (ORR). Secondary outcomes included the median depth of tumor response (DpR), early tumor shrinkage (ETS), R0 resection rate, progression-free survival (PFS), overall survival (not mature at the time of analysis), and safety profile. Radiological tumor evaluations were conducted by radiologists blinded to the group allocation. Primary efficacy analyses were conducted based on the intention-to-treat population, while safety analyses were performed on patients who received at least 1 line of chemotherapy. A total of 14 patients (9.6%) were lost to follow-up (9 in the doublet arm and 5 in the triplet arm). The ORR was comparable following adjustment for stratification factors, with 84.7% versus 79.7% in the triplet and doublet arms, respectively (odds ratio [OR] 0.70; 95% confidence intervals [CI] [0.30, 1.67], Chi-square p = 0.42). Moreover, the ETS rate showed no significant difference between the triplet and doublet arms (80.6% (58/72) versus 77.0% (57/74), OR 0.82, 95% CI [0.37, 1.83], Chi-square p = 0.63). Although median DpR was higher in the triplet therapy group (59.6%, interquartile range [IQR], [50.0, 69.7] versus 55.0%, IQR [42.8, 63.8], Mann-Whitney p = 0.039), the R0/R1 resection rate with or without radiofrequency ablation/stereotactic body radiation therapy was comparable with 54.2% (39/72) of patients in the triplet arm versus 52.7% (39/74) in the doublet arm. At a median follow-up of 26.2 months (IQR [12.8, 40.5]), the median PFS was 11.8 months in the triplet arm versus 13.4 months in the doublet arm (hazard ratio [HR] 0.74, 95% CI [0.50, 1.11], Log-rank p = 0.14). Grade ≥ 3 events were reported in 47.2% (35/74) of patients in the doublet arm and 55.9% (38/68) of patients in the triplet arm. The triplet arm was associated with a higher incidence of grade ≥ 3 neutropenia (44.1% versus 27.0%, p = 0.03) and diarrhea (5.9% versus 0%, p = 0.03). The primary limitations of the study encompass the inherent bias in subjective surgical decisions regarding resection feasibility, as well as the lack of a centralized assessment for ORR and resection. CONCLUSIONS: The combination of cetuximab with FOLFOXIRI did not significantly improve ORR compared to cetuximab plus FOLFOX. Despite achieving an enhanced DpR, this improvement did not translate into improved R0 resection rates or PFS. Moreover, the triplet arm was associated with an increase in treatment-related toxicity. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03493048.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Wang DS, Ren C, Li SS, et al. Cetuximab plus FOLFOXIRI versus cetuximab plus FOLFOX as conversion regimen in RAS/BRAF wild-type patients with initially unresectable colorectal liver metastases (TRICE trial): A randomized controlled trial. PLoS Med. 2024. PMID: 38728364. doi:10.1371/journal.pmed.1004389

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。